ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
Covered in this story
What has happened since
- Adma Biologics Inc is up 2.1% since this was published, 7 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ADMA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Adma Biologics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.